Executive management

BSc in Mechanical Engineering from ETH Zürich and a MEng in Product Development from the KTH Royal Institute of Technology in Stockholm, a MScEng in Industrial engineering and Production, Supply Chain Management and Integrated Product Development and a PhD in Innovation and Technology Management from ETH Zürich.

Owner of Innoverse GmbH.

CEO of Indical Bioscience, various positions at Novozymes and Consultant at Bain & Company.

1,907,812 ordinary shares, 1,214,554 C shares.
Subscribed for a total of 250,836 warrants in the Company under LTI 2021.

MSc in International Economics and Business from the Stockholm School of Economics.

Board member of a number of subsidiaries within the Group and Transferator AB (publ) and board member or deputy board member of a number of subsidiaries within the Transferator AB (publ)-group.

CFO of Nexmune, Group Strategy and M&A Manager at Dometic and Consultant at L.E.K. Consulting.

1,041,910 ordinary shares, 625,146 C shares.
Subscribed for a total of 125,418 warrants in the Company under LTI 2021.

MSc in Business and Economics from the Stockholm School of Economics.

Chairman of the board of a number of subsidiaries within the Group. Board member of a number of subsidiaries within the Group and Nextmune BV, Nextmune US LLC, Nextmune AS, Nextmune Spain S.L., Diavet S.L., I.C.F. S.r.l., DRN S.r.l., and Vetruus Limited.

VP Corporate Strategy and M&A at Meda.

2,143,061 ordinary shares, 1,367,912 C shares.
Subscribed for a total of 125,418 warrants in the Company under LTI 2021.

Bachelor of Economics (Honours) at LUISS Guido Carli University in Rome.

Director at Ontario Teachers’ Pension Plan, Principal at Bain & Company and Consultant at Ernst & Young.

0 ordinary shares, 0 C shares.
0 warrants.

MSc in Finance and Marketing from the Stockholm School of Economics.

Chairman of the board and board member of a number of subsidiaries within the Group. Board member of Saluki AB. Deputy board member of Marie-Louise Design AB.

Group Business Development Director at AniCura, Investment Director at Montagu and Associate at Goldman Sachs.

3,461,635 ordinary shares, 2,209,555 C shares.
0 warrants.

BBA in International Business from Université du Québec à Montréal and a MBA in International Business from University of Illinois at Chicago.

Board member of a number of subsidiaries within the Group.

CEO of Veterinary Orthopedic Implants.

17,256,029 ordinary shares, 7,876,219 C shares.
Subscribed for a total of 125,418 warrants in the Company under LTI 2021.

BSc in Mechanical Engineering from University of Memphis, US.

President and CEO of Biomedtrix and Director of Product Development at Stryker and Zimmer.

419,885 ordinary shares, 370,487 C shares.
0 warrants.

MSc in Management, Technology and Economics from ETH Zürich.

Chairman of the board of KYON AG. Board member of Kyon Pharma (US) and Ossium AG.

CEO of Kyon, General Manager of Joint Replacement Division at Stryker and Sales Manager at Johnson & Johnson.

663,889 ordinary shares, 344,318 C shares.
Subscribed for a total of 83,612 warrants in the Company under LTI 2021.

MSc in Finance from the Stockholm School of Economics.

Board member of HRR Holding AB and Danzinger Gatt Invest AB.

Head of M&A at Doktor.se, Group M&A Manager at AniCura and Investment Manager at Nordic Capital.

174,250 ordinary shares, 104,550 C shares.
0 warrants.

MSc in Accounting and Financial Management from the Stockholm School of Economics.

Group Communications Manager at AniCura, Head of Marketing & Communications at Moderna Försäkringar and Consultant at JKL Group.

7,300 ordinary shares, 0 C shares.
Subscribed for a total of 83,612 warrants in the Company under LTI 2021.